期刊文献+

紫杉醇对ACC-2细胞的体外抗增殖作用 被引量:2

Anti-proliferation of Paclitaxel on ACC-2 Cells in Vitro
暂未订购
导出
摘要 目的 为判断紫杉醇能否有效抑制腺样囊性癌 (ACC)细胞增殖提供实验依据。 方法 通过紫杉醇作用于体外培养的 ACC- 2细胞及 L 92 9细胞 ,采用 MTT法测定细胞活性 ,计算并比较紫杉醇、顺铂 (CDDP)、5 -氟脲嘧啶 (5 - Fu)和阿霉素 (ADM)的 Cmax浓度时的细胞增殖抑制率、IC50 和相对抗肿瘤活性 (RAA)。 结果  Cmax浓度的紫杉醇对 ACC- 2的增殖抑制率为 (70 .46± 1.0 6 ) % ;紫杉醇、CDDP、5 - Fu和 ADM的 IC50 分别为 0 .0 2 ,2 .93,47.0 8和 0 .6 7((g/ m l) ,RAA分别为 18.0 ,1.0 ,0 .2和 0 .6。 结论 四种药物均有抗 ACC- 2细胞增殖作用及抗癌特异性。紫杉醇的单药活性最高 ,抗癌特异性与 CDDP和 Objective\ To investigate whether paclitaxel inhibited ACC\|2 cells efficiently or not, and provide valuable experiment data for clinical treatment of ACC.\ Methods\ In vitro, MTT assay was performed to detect proliferation inhibition rate of paclitaxel\|treated, CDDP\|treated, 5\|Fu\|treated or ADM\|treated ACC\|2 cells.\ IC\-\{50\} and RAA were used to evaluate single agent activity of these agents.\ L929 was used as control group to compare the anti\|cancer specificity of these four agents.\ Results\ With the same C\-\{max\} concentration the inhibition rate of proliferation on paclitaxel, CDDP, 5\|Fu, ADM, ACC\|2 were 70 46%±1 06%, 69 74%±1 83%, 39 44%±4 24% and 52 24%±2 33% respectively; IC\-\{50\} were 0 06, 2 93, 47 08 and 0 67 respectively; RAA were 18 0, 1 0, 0 2 and 0 6 respectively.\ But inhibition rate on L929 cell line were 30 02%±1 10%, 24 56%±2 13%, 56 67%±2 89% and 35 21%±1 61% respectively.\ Conclusion\ Paclitaxel inhibited ACC\|2 cell proliferation in vitro effectively.\ It had the highest single agent activity among these four anti\|tumor drugs.\ It had good anti\|tumor specificity as well as CDDP, 5\|Fu and ADM.\;
出处 《福建医科大学学报》 2001年第3期241-243,共3页 Journal of Fujian Medical University
关键词 紫杉酚 腺样囊性 比色法 细胞培养的 唾液腺肿瘤 paclitaxel carcinoma,adenoid cystic chromatometry cell, cultured
  • 相关文献

参考文献2

二级参考文献10

  • 1Vokes EE,Weichselbaun RR,Lippman SM,et al. The New England Journal of Medicine . 1993
  • 2Markman M. Yale Journal of Biology and Medicine . 1991
  • 3Rowinsky EK,Donehower RC. Seminars in Oncology . 1993
  • 4Roy SN,Horwitz SB. Cancer Research . 1985
  • 5Dunphy FR,Boyd JH,Kim HJ,et al. Cancer . 1997
  • 6Hainsworth JD,Peacock NW,Thomas M,et al. Proceedings of the American Society of Clinical Oncology . 1997
  • 7Forastiere AA,Leong T,Murphy B,et al. Proceedings of the American Society of Clinical Oncology . 1997
  • 8Hitt R,Hornedo J,Colomer R,et al. Seminars in Oncology . 1995
  • 9Hitt R,Pax-Ares L,Hidalgo M,et al. Seminars in Oncology . 1997
  • 10Dunphy FR,Dunleavy TL,Harrison BR,et al. Cancer . 1997

共引文献4

同被引文献13

  • 1林李嵩,林国础,陈万涛,郭伟,姚明.紫杉醇对腺样囊性癌抗瘤作用及对细胞周期的影响[J].中华口腔医学杂志,2001,36(6). 被引量:9
  • 2孙燕.临床肿瘤学手册[M].北京:北京医科大学,中国协和医科大学联合出版社,1992.157.
  • 3李玉新,吴仕文,主编.跟我学Excel 2000中文版.北京:冶金工业出版社,2000.24-51,194-211.
  • 4Microsoft(R)Excel 2000中文版帮助文件.
  • 5Dombernowsky P,Gehl J, Boesgaard M ,et al. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast carcer[J]. Semin Oncot, 1996, 23 (Suppl 11):23-27.
  • 6Fountzilas G, Athanassiadis A, Kalogera-Fountzila A, et al.Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase Ⅱ study conducted by the Hellenic Cooperative Oncology Group[J]. Eur J Cancer,1997,33,1893-1895.
  • 7Donebower RC,Rowinsky EK. Paclitaxel[J]. PPO updates,1994,8:5-8.
  • 8Straubinger RM,Sharma A,Muray M,et al. Novel taxol formulations,taxol-containing liposomes[J]. J Nail Cancer Inst Monoger, 1993,15 : 69-78.
  • 9Sharma A,Mayhew E,Bolicsak L,et al. Activity of paclitaxel liposome formulations against human ovarian tumor xenografta[J]. Int J Cancer, 1997,71,103-107.
  • 10Cabanes A,Briggs KE,Gokhale PC,et al. Comparative in vivo studies with paclitaxel and liposome encapsulated paclitaxel[J]. Int J Oncol, 1998,12:1035-1040.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部